Praxis Precision Medicines Inc
NASDAQ:PRAX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.55
84.83
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Praxis Precision Medicines Inc
Praxis Precision Medicines Inc
In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients.
Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.
In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients.
Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.
You don't have any saved screeners yet
